Former President Donald Trump has outlined a proposal to implement 100% tariffs on generic drugs, a move he suggests would incentivize domestic manufacturing and address national security concerns. This plan, if enacted, could lead to significant shifts in the U.S. pharmaceutical market, potentially affecting the cost and accessibility of widely used medications.
Shifting Production Landscape
Over the past decade, the production of generic drugs has increasingly moved overseas, with India and China emerging as the primary sources. A 2025 report from the Senate Committee on Aging indicates that India supplies approximately half of the generic drugs used in the U.S. Furthermore, China provides about 80% of the active pharmaceutical ingredients (APIs) used by Indian manufacturers. U.S. reliance on foreign manufacturing for these essential medicines has been a point of concern for lawmakers.
A 2023 report by the Coalition for a Prosperous America highlighted China's significant role in supplying common generic drugs, accounting for roughly 95% of ibuprofen imports and 70% of acetaminophen imports into the United States.
Potential Market Impact
Experts suggest that Trump's proposed tariffs could have far-reaching consequences for both the price and availability of generic drugs. Generic medications constitute a substantial portion of pharmaceutical sales in the U.S., making up about 90% of the market. The tariffs are seen by some analysts as a forceful message to the generics industry: either increase domestic production or face significant market exclusion.
"Tariffs are most effective when they are threatened but not actually applied," noted one expert to TIME. "Here, the administration is sending a ‘Made in America' message to the generics industry: In other words, make it here or sell it elsewhere."
This strategy aims to bolster American manufacturing capabilities, but the immediate impact on consumers could be substantial. A sudden increase in tariffs could disrupt supply chains, leading to higher costs for medications that are critical for millions of Americans. The long-term effects would depend on the industry's ability to adapt and relocate production facilities back to the United States, a process that could be both time-consuming and expensive.